News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


Moleculin Biotech (MBRX) Announces FDA Orphan Drug Designation for its Brain Tumor Drug


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This drug is a new class called "immune transduction modifiers" and targets 3 important markers: STAT3, HIF1-a and c-Myc as well as JAK2..  Will keep an eye on this one. There is a clinical trial in Texas:   https://clinicaltrials.gov/ct2/show/NCT01904123


Posted on: 02/05/2019

Moleculin Biotech (MBRX) Announces FDA Orphan Drug Designation for its Brain Tumor Drug

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740